An unexpected finding after endoscopic management for dysplastic Barrett’s esophagus

Rajit A. Gilhotra, Angad Walia, Wei Xiong, Roberto Trasolini, Neal ShahidiiGIE 2024 · DOI

TL;DR

This paper reports a rare case of esophageal squamous papillomatosis (ESP) developing in a patient after endoscopic submucosal dissection (ESD) and radiofrequency ablation for dysplastic Barrett's esophagus. This finding expands our understanding of potential adverse events associated with these advanced endoscopic treatments for Barrett's esophagus.

What Problem Does This Paper Address?

Barrett's esophagus (BE) is a precancerous condition where the lining of the esophagus changes, increasing the risk of esophageal adenocarcinoma. Endoscopic treatments like endoscopic submucosal dissection (ESD) and radiofrequency ablation (RFA) are used to remove dysplastic or cancerous tissue and ablate remaining abnormal mucosa. While these treatments are generally effective, there's a need to understand all potential outcomes, including rare complications or unexpected findings that might arise post-treatment. This paper addresses the gap in knowledge regarding the development of esophageal squamous papillomatosis (ESP) as a consequence of these interventions.

Methods

The study describes a case report of a 78-year-old male patient with Barrett's esophagus who underwent ESD for early esophageal cancer, followed by RFA for residual BE. Surveillance gastroscopies were performed at 3 and 6 months post-procedure. Histopathology, including hematoxylin and eosin staining and human papilloma virus (HPV) immunostaining, was used to characterize the tissue findings.

  • Endoscopic Submucosal Dissection (ESD): A minimally invasive endoscopic technique used to remove cancerous or precancerous lesions from the gastrointestinal tract.
  • Radiofrequency Ablation (RFA): An endoscopic therapy that uses radiofrequency energy to destroy abnormal cells in the esophagus, commonly used for residual BE after ESD.
  • Histopathology: Microscopic examination of tissue samples to diagnose diseases. In this case, it was used to identify the nature of the polypoid tissue.
  • Immunostaining: A technique using antibodies to detect specific proteins or antigens in tissue, used here to rule out HPV involvement.

Datasets

Not discussed in the paper. This is a case report, not a study involving large datasets for training or evaluation.

Key Insights and Ideas

  • ESP as a Post-Endotherapy Finding: The most significant insight is the identification of esophageal squamous papillomatosis (ESP) developing in a patient after undergoing both ESD and RFA for Barrett's esophagus. This suggests that the inflammatory or healing processes following these aggressive endoscopic interventions might, in rare instances, lead to the development of ESP.
  • ESP is Typically Benign but Can Be Associated with Dysplasia/Cancer: While ESP is generally considered a benign condition with a low risk of malignant progression, historical data suggests it can sometimes be associated with dysplasia and even squamous cell carcinoma. This underscores the importance of thorough histopathological evaluation of any new findings.
  • HPV Exclusion: The study confirmed that the identified ESP was not associated with high-risk human papilloma virus (HPV) infection, which is a known risk factor for other squamous lesions in the esophagus. This suggests that the development of ESP in this context might be driven by factors other than HPV, possibly related to the endoscopic treatment itself.
  • Expanding the Spectrum of BE Treatment Complications: This case broadens the known spectrum of potential adverse events associated with advanced endoscopic management of BE, highlighting that unexpected benign proliferations can occur.

Key Results

  • A 78-year-old male with BE underwent successful ESD for early esophageal cancer, followed by RFA for residual BE.
  • At 6 months post-procedure, surveillance gastroscopy revealed extensive fleshy pink polypoid tissue at the previous ESD site.
  • Histopathology confirmed this tissue to be esophageal squamous papillomatosis (ESP) with no cytologic atypia.
  • Immunostaining excluded human papilloma virus involvement.
  • The authors state this is the first reported case of ESP developing after ESD and RFA for BE.

Limitations and Future Work

  • Case Report Nature: As a single case report, the findings are not generalizable to the broader patient population undergoing BE treatment. It's difficult to establish a definitive causal link between the endoscopic procedures and the development of ESP without further studies.
  • Rarity of the Event: Esophageal squamous papillomatosis is itself a rare condition (estimated prevalence of 0.01% to 0.45%), making its occurrence after specific endoscopic interventions even rarer.
  • Future Work: The authors suggest that this case expands our knowledge of potential BE endotherapy-related adverse events. Further research, potentially through larger retrospective studies or registries, would be needed to determine the true incidence of ESP following ESD and RFA and to explore potential mechanisms. Understanding the specific factors that might predispose patients to this complication could inform future management strategies.

Summary updated

BibTeX
@inproceedings{gilhotra2024unexpected,
  author = {Rajit A. Gilhotra and Angad Walia and Wei Xiong and Roberto Trasolini and Neal Shahidi},
  title = {{An unexpected finding after endoscopic management for dysplastic Barrett’s esophagus}},
  booktitle = {iGIE},
  year = {2024},
  doi = {10.1016/j.igie.2024.09.006},
}
Figure